Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer

Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). It is a novel chemotherapeutic agent currently approved as part of combination chemotherapy for metastatic colorectal cancer, non-small cell lung cancer, and breast cancer (Hurwitz et al 2004; Sandler et al...

Descripción completa

Detalles Bibliográficos
Autores principales: Franco, Thérèse H, Khan, Ahmed, Joshi, Vishal, Thomas, Beje
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643117/
https://www.ncbi.nlm.nih.gov/pubmed/19337443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2643117/
https://www.ncbi.nlm.nih.gov/pubmed/19337443

Ejemplares similares